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Background: Bacterial resistance to antibiotics is a major pub-
lic health problem. In Africa, few data are available however in this
ﬁeld. Thus, at the Hopital Principal of Dakar, a data collecting sys-
tem andmonthly resistance analyses has been implemented by the
Committee against nosocomial infections (CLIN). We present here
the results compiled over a year to help guide prevention activities.
Methods & Materials: This is a prospective study from January
1 to December 31, 2012 in the various departments of Hopital
Principal. Every day, multiresistant laboratory isolates are sub-
ject to clinical and biological data collection using a questionnaire,
this after removing duplicates. These isolates include Entero-
bacteriaceae producing extended-spectrum beta-lactamase (ESBL)
and derepressed cephalosporinase, multiresistant Pseudomonas
aeruginosa and Acinetobacter (Ceftazidime and/or imipenem resis-
tant), Staphylococcus aureus Methicillin Resistant (MRSA). Was
considerednosocomial origin any infection revealing after 48hours
of hospitalization. The data are then analyzed with Epi Info.
Results:Threehundred and sixty (360)MRBwere collecteddur-
ing the study period. The average age was 32 years [4 days, 95
years] with a sex ratio of 1.70. It was essentially ESBL-producing
Enterobacteriaceae (87%) followed by multiresistant Acinetobacter
(8%), multiresistant Pseudomonas aeruginosa (2%) and methicillin-
resistant Staphylococcus aureus (3%), respectively. ESBLs were as
follows: Klebsiella (59%), E. coli (24%), Enterobacter (12%), and the
remaining (5%). Bacteremia was the most common sites (45%), fol-
lowed respectively by urinary tract infections (30%) and abscesses
(15%).According to the incidencedensityper1000patient-days, the
most affected departments were respectively intensive care units
(7 ‰), Pediatrics (5.4 ‰), Medicine (2.7 ‰) and ﬁnally surgery (1.1
‰). A catheter was present in 91% of patients with sepsis and 66%
of infections with ESBL-producing Enterobacteriaceae were con-
sidered as nosocomial origin.
Conclusion: This study shows the need for Hopital Principal of
Dakar to prevent more effectively the spread of MRB (especially
ESBL) through an extension of hand washing especially with the
use of alcoholic solutions and a more rational use of antibiotics.
http://dx.doi.org/10.1016/j.ijid.2014.03.633
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Comparison of susceptibility trends of
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Background: Resistance rates vary regionally, with rates often
higher in poorer countries. The Study for Monitoring Antimicrobial
Resistance Trends (SMART) has tracked susceptibility of Gram-
negative pathogens (GNP) of intra-abdominal infections (IAI) since
2002. This report compares susceptibility of E. coli in high-income
(HI) and low-to-middle income (LMI) countries since 2008.
Methods & Materials: Sites in 34 countries each collected up to
100 consecutively isolatedGNP from IAI per year. Susceptibility and
ESBL phenotypes were determined using CLSI broth microdilution
for 24,406 E. coli collected between 2008 and 2012. Only countries
submitting isolates all 5 years were included, and were catego-
rized as HI or LMI usingWorld Bank criteria (www.worldbank.org).
Although only data for 2008 and 2012 are shown below, suscep-
tibility and ESBL+ trends were assessed for signiﬁcance with the
Cochran-Armitage test using all 5 years. Susceptibility in 2012 was
compared between HI and LMI countries with the Chi Square test.
Results: E. coli ESBL+ rates (%) in 2008/2012 were 10.2/12.6 and
33.7/46.4 forHI and LMI, respectively. Both trendswere statistically
signiﬁcant (p <0.05).
Conclusion: In vitro susceptibility levels remained fairly con-
stant in HI countries from 2008 to 2012. Although trends for
most drugs were statistically signiﬁcant, percentage differences
were small. In contrast, susceptibility decreased much more in
LMIcountries,withonlyamikacin, cefoxitin, ertapenem, imipenem,
andpiperacillin-tazobactam inhibiting >70%ofE. coliby2012.Com-
pared to HI countries, all drugs were signiﬁcantly less active in LMI
in 2012; ampicillin-sulbactam, all cephalosporins except cefoxitin,
and ﬂuoroquinolones had relatively large differences in suscepti-
bility between HI and LMI countries.Given the higher ESBL+ rates
observed in LMI countries, these differences are not unexpected,
as co-resistance in ESBL+ isolates to many of these drugs is well-
documented. ESBL+ rates and resistance rates are not only higher
in LMI than HI countries, but are increasing faster as well.
http://dx.doi.org/10.1016/j.ijid.2014.03.634
